London, UK -- (SBWIRE) -- 11/14/2018 -- Analyst Speak:
"The Global Female Fertility Drugs Market was growing at a significant CAGR over seven years forecast period 2018-2024 owing to rise in the prevalence of infertility condition"
Precision Business Insights (PBI) in its report titled "Global Female Fertility Drugs Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013 - 2017 and Forecast 2018-2024" assesses the market performance over seven years forecast period over 2018-2024. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.
The global female fertility drugs market was growing at a significant CAGR over the forecast period owing to rise in the prevalence of infertility cases due to change in the lifestyle, government initiatives for the infertility management, and increase in disposable income are driving the female fertility drugs market over the forecast period. Moreover, rise in R&D activities for the development of novel drugs to treat the infertility conditions, rise in prevalence of obesity, and increase in the maternal age are expected to boost the female fertility drugs market. However, stringent regulatory policies for new drug approvals, lack of awareness regarding female fertility drugs in low economic countries, and alternative infertility treatments such as in vitro fertilization are restraining the growth of the global female fertility drugs market over forecast years.
Sample of this report is available upon request @
Global female fertility drugs market segmented on the basis of drug type, distribution mode, and route of administration, distribution channel and region
Gonadotropins Female Fertility Drugs Accounted For Higher Revenue Share
Based on drug type, global female fertility drugs market segmented into gonadotropins, aromatase inhibitors, selective estrogen receptor modulators, follicle stimulating hormones, dopamine agonists, metformin hydrochloride and others. Gonadotropins segment accounted for larger revenue share in 2017 and projected to dominate over the forecast period owing to rise in the prevalence of infertility cases. Moreover, mergers & acquisitions, collaborations, product developments and product launchings are the major strategies followed by the companies to increase their market revenue share in the female fertility drugs market.
North America leads the Global Female Fertility Drugs market
PBI's global female fertility drugs market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. According to regional analysis, North America accounted for larger revenue share in 2017 and the same trend is projected to follow over 2018-2024 owing to increase in the prevalence of female infertility rate due to obesity and lifestyle changes, increase in R&D activities for the innovation of novel molecules, and rise in awareness about the fertility drugs among the stakeholders in the region. Europe female fertility drugs market projected to exhibit significant growth due to accessibility and increase in infertility rate in female due to hormonal imbalance, and lifestyle changes are the factors that are creating lucrative opportunities in the European region for female fertility drugs market players.
TOC of this report is available upon request @
Product approvals, launch of new products and strategic alliances are the key strategies adopted by the market players
Global female fertility drugs market further reveals that the key player's increasingly adopting strategies such as product launch and long term alliance to improve market revenue share and gaining significant geographic presence across the region. For instance, in May 2017, Merck KGaA received European Commission Grants approval for Pergoveris prefilled injection used in the treatment of follicle stimulating hormone (FSH) and Luteinizing hormone (LH) deficiency.
Key player's profile in the report are Sanofi S.A. (France), Merck KGaA (Germany), Novartis AG (Switzerland), Ferring B.V. (Switzerland), Berlex Laboratories Inc. (U.S.), Eli Lilly and Co. (U.S.), Novogyne Pharmaceuticals (U.S.), and Pfizer, Inc. (U.S.).
Ask Analyst for Full Information about this report @
By Drug Type
o Aromatase Inhibitors
o Selective Estrogen Receptor Modulators
o Follicle Stimulating Hormones
o Dopamine Agonists
o Metformin Hydrochloride
By Distribution Mode
o Prescription Fertility Drugs
o Over-The-Counter Fertility Drugs
By Route of Administration
By Distribution Channel
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o North America
- Rest of Europe
- Australia & New Zealand
- Rest of Asia-Pacific
o Rest of World
- South Africa
- Saudi Arabia
Get access to full summary @
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
152 – 160 City Road,
London EC1V 2NX
Contact Person: Rajesh Babu
Role: Marketing Lead
Toll Free (US):+1-866-598-1553